动态检测非小细胞肺癌患者手术前后血清骨桥蛋白水平的临床意义

Dynamic determination of serum osteopontin level in Pre-and postoperative patients with non-small cell lung cancer

目的 研究非小细胞肺癌(NSCLC)患者术前血清骨桥蛋白浓度与临床特征的关系以及骨桥蛋白作为NSCLC肿瘤标志物的价值.探讨手术前后血清骨桥蛋白水平的动态检测及其临床意义.方法 采用酶联免疫吸附法(ELISA)检测88例NSCLC患者手术前后血清中骨桥蛋白水平.结果 NSCLC患者血清中骨桥蛋白水平显著高于良性肺疾病患者(P＜0.05)和健康对照组(P＜0.01).血清骨桥蛋白水平与NSCLC的临床分期及淋巴结转移情况显著相关.Ⅲ～Ⅳ期NSCLC患者血清骨桥蛋白水平明显高于Ⅰ～Ⅱ期;淋巴结转移组高于非淋巴结转移组;术后血清骨桥蛋白水平明显低于术前(P＜0.01).血清骨桥蛋白与肿瘤的分化程度无关.血清骨桥蛋白检测对88例NSCLC诊断的灵敏度(Se)为84.1%,特异度(Sp)为92.5%,准确度为88.1%.结论 血清骨桥蛋白可作为NSCLC较理想的肿瘤标志物.动态检测手术前后血清骨桥蛋白水平对NSCLC的诊断、判断预后、指导治疗和鉴别肺良恶性病变有一定参考价值.

Objective To explore the change of serum osteopontin levels in preoperative and postoperative patients with non-small cell lung cancer (NSCLC) and its clinic significance.Methods The levels of serum osteopontin were detected by ELISA.Results In 88 NSCLC patients,serum osteopontin levels were significantly higher than in benign pulmonary disease and healthy control group(P＜0.05.P＜0.01.respectively) There was no difference between benign pulmonary disease and healthy control group(P＞0.05).Serum osteopontin levels were related to clinical stage and lymph node metastasis,and the levels of serum osteopontin were lower in postoperative patients than in preoperative cases(P＜0.05).For NSCLC.the detection of osteopontin had a sensitivity of 84.1%,a specificity of 92.5%,and an accuracy of 88.1%. Conclusion Increased serum levels of osteopontin may be useful as a helpful clinical biomarker to diagnose earlier,predict prognosis and differentiate from benign pulmonary disease.